Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant

Therapeutic Drug Monitoring

Volumn 36, Issue 5, 2014, Pages 624-631

  Mani, Helen ^a   Herth, Natalie ^a   Kasper, Alexander ^a   Wendt, Thomas ^b   Schuettfort, Gundolf ^a   Weil, Yvonne ^a   Pfeilschifter, Waltraud ^a   Linnemann, Birgit ^a   Herrmann, Eva ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Cardio Health Center   (Germany)

Author keywords

dabigatran; point of care testing; rivaroxaban; therapeutic drug monitoring

Indexed keywords

DABIGATRAN; PHENPROCOUMON; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACTIVATED CLOTTING TIME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS EQUIPMENT; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MINIMUM PLASMA CONCENTRATION; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTHROMBIN TIME; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; CONTROLLED CLINICAL TRIAL; DEVICES; DRUG EFFECTS; HOSPITAL INFORMATION SYSTEM; MIDDLE AGED; PROCEDURES; STANDARDS; YOUNG ADULT;

ADULT; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PHENPROCOUMON; POINT-OF-CARE SYSTEMS; THIOPHENES; YOUNG ADULT;

EID: 84930177592     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000064     Document Type: Article

References (33)

1. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-e88S.
2. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res. 2012; 130:S88-S89.
3. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010;113:726-745.
4. Spahn DR, Korte W. Novel oral anticoagulants: new challenges for anesthesiologists in bleeding patients. Anesthesiology. 2012;116:9-11.
5. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost. 2011;106:156-164.
6. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012;130:956-966.
7. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371-378.
8. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations monitoring dabigatran etexilate. Thromb Haemost. 2012;107: 985-997.
9. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-1127.
10. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012;159:427-429.
11. Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: A new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376-381.
12. EMA-Rivaroxaban. Summary of product characteristics. 2012. Available at: https://www. medicines. org. uk/emc/medicine/25586/SPC/.
13. Samama MM, Contant G, Spiro TE, et al. Rivaroxaban prothrombin time field trial laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost. 2012;18:150-158.
14. Harenberg J, Marx S, Weiss C, et al; on behalf of the working party: methods to determine rivaroxaban of the Subcommittee on Control of Anticoagulation of the ISTH. Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433-1436.
15. Walter S, Kostopoulos P, Haass A, et al. Point-of-care laboratory halves door-to-therapy-decision time in acute stroke. Ann Neurol. 2011;69:581-586.
16. Tschaikowsky K, Balint R, Pscheidl E, et al. Prothrombin time and thromboplastin time. On-site measurement of the prothrombin time and activated partial thromboplastin time of surgical patients with laser photometry. Anaesthesist. 1998;47:295-302.
17. Boldt J, Walz G, Triem J, et al. Point-of-care (POC) measurement of coagulation after cardiac surgery. Intensive Care Med. 1998;24: 1187-1193.
18. Hirsch J, Wendt T, Kuhly P, et al. Point-of-care testing apparatus. Measurement of coagulation. Anaesthesia. 2001;56:760-763.
19. Rohde G. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43-50.
20. Douxfils J, Dogné JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost. 2013;110:543-549.
21. Samama MM, Contant G, Spiro TE, et al. Rivaroxaban anti-factor Xa chromogenic assay field trial laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107: 379-387.
22. Harenberg J, Krämer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32:267-271.
23. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108:191-198.
24. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-143.
25. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457-507.
26. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med. 2011;49:755-757.
27. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis. 2013;36:187-194.
28. Harenberg J, Du S, Krämer S, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost. 2013;39:66-71.
29. Meyer Dos Santos S, Zorn A, Guttenberg Z, et al. A novel m-fluidic whole blood coagulation assay based Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants. Biomicrofluidics. 2013; 7:56502.
30. Eller T, Busse J, Dittrich M, et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med. 2014:1-10. doi: 10. 1515/ cclm-2013-0936.
31. Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J. 2014;31:163-168.
32. Makris M, Van Veen JJ, Tait CR, et al; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160:35-46.
33. EMC. Summary of product characteristics: Pradaxa. 2012. Available at: http://www. medicines. org. uk/emc/medicine/24839/SPC/. Accessed September 14, 2012.